SNS-301 was administered intradermally every 21 days in a 3+3 dose-escalation trial evaluating 3 dose levels to patients with biochemically (rising PSA) relapsed prostate cancer with evidence of ASPH over-expression as detected in serum. This evidence concerns the gene KLK3 and Familial prostate cancer.